Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1.

Intravenous administration of liposome-encapsulated hemoglobin (LEH) in rats led to an early (within 15 min) decline of hemolytic complement (C) activity in the plasma along with a significant, parallel rise in thromboxane B2 (TXB2) levels. The TXB2 response was inhibited by co-administration of soluble C receptor type 1 (sCR1) with LEH, as well as by C depletion with cobra venom factor. These observations provide evidence for a causal relationship between LEH-induced C activation and TXB2 release, and suggest that sCR1 could be useful in attenuating the acute respiratory, hematological and hemodynamic side effects of LEH described earlier in the rat.

[1]  C. Alving,et al.  Complement activation in vitro by the red cell substitute, liposome‐ encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1 , 1997, Transfusion.

[2]  H. Frierson,et al.  Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. , 1996, The Annals of thoracic surgery.

[3]  Pierson Rn rd,et al.  Thromboxane mediates pulmonary vasoconstriction and contributes to cytotoxicity in pig lungs perfused with fresh human blood. , 1996 .

[4]  T. Davis,et al.  Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels. , 1996, Experimental hematology.

[5]  N. Jamieson,et al.  Regulation of the complement cascade by soluble complement receptor type 1. Protective effect in experimental liver ischemia and reperfusion. , 1995, Transplantation.

[6]  A. Cheung,et al.  Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. , 1994, Kidney international.

[7]  S. Chang,et al.  TNF potentiates PAF-induced pulmonary vasoconstriction in the rat: role of neutrophils and thromboxane A2. , 1994, Journal of applied physiology.

[8]  C. Alving,et al.  Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. , 1994, Biochemical and biophysical research communications.

[9]  A. Kirk,et al.  The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. , 1994, Transplantation.

[10]  W. Baumgartner,et al.  Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. , 1993, The Annals of thoracic surgery.

[11]  B. Lucchesi,et al.  Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart. , 1993, Journal of immunology.

[12]  E. Sim,et al.  The interaction of soluble human complement receptor type 1 (sCR1, BRL55730) with human complement component C4. , 1993, Biochimica et biophysica acta.

[13]  B. Goins,et al.  In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[15]  T. Hugli,et al.  Endotoxin-induced shock in the rat. A role for C5a. , 1989, The American journal of pathology.

[16]  S. Christensen,et al.  Preparation of human hemoglobin Ao for possible use as a blood substitute. , 1988, Journal of biochemical and biophysical methods.

[17]  T. Hugli,et al.  Effects of the anaphylatoxins on circulation. , 1987, Immunopharmacology.

[18]  H. Müller-Eberhard,et al.  Cobra venom factor: improved method for purification and biochemical characterization. , 1984, Journal of immunological methods.

[19]  L. Argiolas,et al.  Cardiopulmonary Effects of Endothelin‐1 in the Guinea Pig: Role of Thromboxane A2 , 1995, Journal of cardiovascular pharmacology.

[20]  C. Alving,et al.  Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. , 1995, Artificial cells, blood substitutes, and immobilization biotechnology.

[21]  K. Vandegriff,et al.  Blood substitutes : physiological basis of efficacy , 1995 .

[22]  B. Gaber,et al.  Liposome-encapsulated hemoglobin as an artificial oxygen-carrying system. , 1987, Methods in enzymology.